Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
GNLX
Stock Latest News
Company Announcements
Genelux Corp. Lowers Stock Option Exercise Prices
9d ago
8K
GNLX
Premium
Ratings
Genelux Corp.’s Innovative Cancer Treatment Approach Earns Buy Rating
1M ago
GNLX
Premium
Ratings
Promising Outlook for Genelux Corp. with Olvi-Vec Advancements and Strong Financial Position
1M ago
GNLX
Premium
Ratings
Promising Potential of Genelux Corp.’s Olvi-Vec in Oncology: A Buy Rating Based on Clinical Data and Strategic Developments
1M ago
GNLX
Premium
The Fly
Genelux reports Q2 EPS (20c), consensus (22c)
1M ago
GNLX
Premium
Ratings
Promising Prospects for Genelux Corp.’s Olvi-Vec: A Buy Rating Based on Strong Clinical Trial Design and Efficacy
2M ago
GNLX
Premium
The Fly
Genelux initiated with a Buy at Lucid Capital
2M ago
GNLX
Premium
Ratings
Genelux Corp: A Promising Investment in the Oncolytic Virus Space with Key Clinical Milestones Ahead
2M ago
GNLX
Premium
The Fly
Genelux appoints Eric Groen as general counsel, corporate secretary, CCO
2M ago
GNLX
RANI
Premium
Ratings
Genelux Corp.’s Promising Prospects: Buy Rating Backed by Strong Phase 3 Trial and Financial Position
4M ago
GNLX
Premium
Ratings
Promising Developments in Genelux Corp.’s Olvi-Vec Drive Buy Rating
4M ago
GNLX
Premium
The Fly
Genelux reports Q1 EPS (21c), consensus (24c)
4M ago
GNLX
Premium
Ratings
Genelux Corp. Buy Rating: Strategic Financial Positioning and Growth Prospects Amid Clinical Advancements
6M ago
GNLX
Premium
The Fly
Genelux reports FY24 EPS (95c), consensus (88c)
6M ago
GNLX
Premium
Ratings
Promising Clinical Trial Results and Strong Financial Position Justify Buy Rating for Genelux Corp.
6M ago
GNLX
Premium
The Fly
Genelux, Newsoara announce preliminary Phase 1b/2 data of Olvi-Vec
6M ago
GNLX
Premium
The Fly
Genelux announces alignment with FDA of approval pathway for Olvi-Vec
6M ago
GNLX
Premium
The Fly
Genelux prices 3M shares at $3.50 in underwritten public offering
6M ago
GNLX
Premium
The Fly
One new option listing on February 19th
7M ago
GNLX
Premium
The Fly
Genelux names Matthew Pulisic as CFO, effective January 30
7M ago
ARWR
GNLX
Premium
Company Announcements
Genelux Corp. Appoints New CFO Amid Leadership Change
7M ago
8K
GNLX
Premium
The Fly
Biotech Alert: Searches spiking for these stocks today
8M ago
INM
IPA
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
